Represented a private investment firm in a healthcare regulatory diligence for their purchase of NovaMed Inc.
Represented a private investment firm focused on the lower middle market, in its leveraged buyout of a designer, manufacturer and seller of equipment and scientific instruments for plants and laboratories in the industrial, biomedical, hospital, educational and governmental markets.
Represented a private investment firm through its portfolio company, in their recent merger agreement with an operator of ambulatory surgery centers in partnership with physicians . The transaction was valued at approximately $214 million, including the assumption or repayment of approximately $105 million of indebtedness.
Represented a private equity firm focused on market leaders in healthcare in its acquisition of the nation’s leading provider of infusion products, supplies, biomedical services and technology solutions to the home infusion therapy market. We advised on the healthcare regulatory aspects of the transaction.
Represented a provider of non-emergency, inter-facility transport services on a pre-scheduled basis to patients requiring medical care in its sale to a private equity fund focused on providing capital to lower-middle market growth companies in the healthcare services industry.
Christopher Greene Appointed Managing Partner of McGuireWoods’ Atlanta Office
July 26, 2018
Mergers & Acquisitions Magazine Names McGuireWoods “Law Firm of the Year”
March 21, 2018
Smart Investing in Primary Care Centers: 5 Key Takeaways
April 16, 2018
Dermatology Spotlight Panel: 5 Key Points
April 10, 2018
HIPAA in Due Diligence (Part III): Risk Mitigation Strategies
April 4, 2018
HIPAA in Due Diligence (Part II): Cloud Server Data and HIPAA Compliance
April 2, 2018
Investments in Dental Services Organizations: 5 Key Considerations
April 2, 2018